ORIC Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ORIC | AVBP | ANL | SNDX | RCUS | 9966.HK | |
|---|---|---|---|---|---|---|
| Market cap | 968.12M | 665.16M | 618.86M | 940.80M | 2.43B | 6.43B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.5 | -3.6 | -32.7 | -14.4 | -6.2 | -21.0 |
| Price/book | 2.5 | 1.8 | 2.9 | -54.7 | 3.8 | 3.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −22.54% | −28.97% | +560.69% | −5.36% | −4.25% | −39.84% |
| Today | −2.61% | +3.61% | +0.31% | −26.87% | +2.12% | +1.68% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ORIC news ›Akums Drugs Acquires Oriflame India's Manufacturing Business for Rs 56 Crore, Reports 168% Surge in Q2 FY27 Net Profit
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information,…
ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data
MangoStar_Studio from Getty Images via Canva ORIC Pharmaceuticals (ORIC) is down 22% today, and the bad news isn’t even its own. Over the weekend, Johnson & Johnson (JNJ) presented early data on its experimental prostate cancer drug,…
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Cut by Wedbush
Posted by Michael Walen on Oct 27th, 2026 Oric Pharmaceuticals (NASDAQ:ORIC – Get Free Report) had its price target dropped by stock analysts at Wedbush from $17.00 to $14.00 in a research report issued on Tuesday, Benzinga reports. The…
More from 1 other outlet
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer October 23,... ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and…
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ETEvent to feature Dr. Joshua Sabari to discuss enozertinib cl... ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being…
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO...
Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergenc
More from 2 other outlets
- MarketScreener Oric Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer At Esmo Congress 2026
- Stock Titan ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
Wells Fargo Remains a Buy on Oric Pharmaceuticals (ORIC)
Wells Fargo analyst Derek Archila maintained a Buy rating on Oric Pharmaceuticals on October 16 and set a price target of $25.00. The company’s shares closed last Friday at $12.35. Archila covers the Healthcare sector, focusing on stocks…
Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
Posted by Sarita Garza on Oct 24th, 2026 Oric Pharmaceuticals (NASDAQ:ORIC) reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations,…
Transcript : ORIC Pharmaceuticals, Inc. - Special Call
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the ORIC Enozertinib Program Update Call. [Operator Instructions] Please be advised that today's conference Transcript : ORIC Pharmaceuticals, Inc. -…
ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer Data
ORIC Pharmaceuticals (ORIC) presented clinical data for enozertinib, an investigational EGFR inhibitor, in patients with previously untreated non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations at the ESMO Congress 2026.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com6
- marketscreener.com4
- stocktitan.net3
- marketbeat.com2
- themarketsdaily.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 23 articles, not a forecast.